

Disclosure Statement

Joint Working Project between;

- Hull and East Yorkshire Hospitals NHS Trust (HEY) and Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)

Name of Project	Pathway Improvement for Anti-Cancer Therapies
Project Overview	<p>Immuno-oncology (I-O) therapies are relatively new within Hull and East Yorkshire Hospitals NHS Trust (HEY). Clinical indications and the number of eligible patients for I-O therapy are continuing to increase, the result of which will be a greater demand and pressure on hospital resources. Like for like, patients on I-O therapies require more hospital appointments/admissions for treatment compared to conventional treatments. If nothing were to change, the centre might be unable to accommodate this demand and cancer waiting times and patient experience might be detrimentally affected. For this reason, the service has considered it prudent to initiate a project to review the total patient pathway for both oncology/haematology elective treatments. The project aims to address:</p> <ul style="list-style-type: none"> • How to alleviate the capacity pressure point at the point of administration of oncology/haematology medicines both in the infusion suite and aseptic pharmacy, giving specific attention to: <ul style="list-style-type: none"> ○ The growing number of tumour types (viz. lung, melanoma, renal, bladder, head and neck) where I-O therapies would be included as part of the clinical management; ○ Rapidly escalating numbers of patients in whom I-O therapies would be a treatment option in the future; ○ Consideration of key capacity elements such as SACT, outpatients, staff, resources and accommodation; ○ A safe, sustainable, efficient and integrated service model for both now and in the future ○ A reduction in the wastage of oncology/haematology medicines <p>The Queens Centre within HEY is a state of the art facility but as treatments are changing it is rapidly outgrowing its accommodation. The main task of the centre is to maximise every resource, streamline processes to ensure the best patient care and further understand the accommodation and resource implication for the future to be sustainable.</p>
Project Objectives	<ul style="list-style-type: none"> • To maximise and reduce wastage of resources in the pathway of anti-cancer treatment and subsequent reviews/treatments, both in the short term and a longer time frame (2021) • To maintain or reduce the time between decision to treat and administration of anti-cancer treatment and subsequent reviews/treatment • Ensure that patient anxiety is minimised through controllable elements within the patient journey and that this then leads to greater patient satisfaction • Better understand the demand on accommodation and resources for the longer term with the impact on I-O therapies
Patient Benefits	<ul style="list-style-type: none"> • Improved patient experience and reducing potential anxiety that may be felt by some patients about the duration of time from decision to treat (DTT) to treatment administration • A service that meets the patient/service user requirements and needs and is consistent with person-centred values (for example: choice, control, independence, empowerment) • Improved patient experience through provision of a streamlined, efficient and patient focused service
Stakeholders	Hull and East Yorkshire Hospitals NHS Trust (HEY) Bristol Myers-Squibb Pharmaceuticals Ltd (BMS)
Timelines	The Project will start from the date on which the disclosure statement goes live on the BMS website and will finish 12 months after this date

Produced by **Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)** with **Hull and East Yorkshire Hospitals NHS Trust (HEY)**

ONCUK1900121-03
Date of Preparation: January 2019